Tumor immune evasion arises through loss of TNF sensitivity
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Whole-genome CRISPR screens identify resistance to TNF-mediated killing by T and NK cells as a tumor immune evasion mechanism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IFN γ and TNF α are key effector cytokines that contribute to anti-tumour immune responses 9,11,27-30 , and genes associated with IFN and TNF signaling pathways contribute to immune evasion 4,9,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [29]
In the citing paper
“Single-guide RNAs targeting genes involved in IFN γ sensing (Ifngr1, Ifgnr2, Jak1, Jak2, and Stat1) were enriched in control and Tbk1-null cells (Fig. 5d, Extended Data Fig. 10a), consistent with previous in vivo and in vitro screens 4,29 .”
From Targeting TBK1 to overcome resistance to cancer immunotherapy (2023) · cites this paper as [29]
Citations
Cites
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 1×
“The mouse cell lines MC38-Cas9, MC38OvaCas9, and B16Ova-Cas9 cells were transduced with the Brie genome-wide sgRNA library (40), and the human cell line MDA-MB-231 was transduced with the Brunello genome-wide sgRNA library.”
MethodMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 3×
“Gene mutations that reduce the efficacy of immunotherapy have recently been identified, including mutations in Janus kinases (JAK) providing resistance to anti–PD-1 therapy (9).”
BackgroundClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Li, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Perforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
Self-citationGenome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243 · cited 1×
“Genomic DNA extraction was subsequently performed using the DNeasy Blood & Tissue Kit (Qiagen), and libraries were prepared as described previously (41).”
MethodIn vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Cited by
Items 201–300 of 405
CRISPR Screens to Identify Regulators of Tumor Immunity
LaFleur, M. W., & Sharpe, A. H. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070120-094725 · Cited by 16
Connexin channels modulation in pathophysiology and treatment of immune and inflammatory disorders
Tittarelli, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166258 · Cited by 16
A Squalene-Based Nanoemulsion for Therapeutic Delivery of Resiquimod
Zhang, Z., Kuo, J. C., Zhang, C., Huang, Y., Zhou, Z., & Lee, R. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122060 · Cited by 16
Zhang, Z., Chen, X., Zhang, B., Zhang, W., & Ding, Z.-Y. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189517 · Cited by 15
Logun, M. T., Colonna, M. B., Mueller, K. P., Ventarapragada, D., Rodier, R., Tondepu, C., Piscopo, N. J., Das, A., Chvatal, S. A., Hayes, H. B., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.008 · Cited by 15
Yang, P., He, S., Ye, L., & Weng, H. (2024) · International Archives of Allergy and Immunology · doi:10.1159/000537754 · Cited by 15
Feng, H.-R., Shen, X., Zhu, X., Zhong, W.-T., Zhu, D.-X., Zhao, J., Chen, Y.-J., Shen, F., Liu, K., & Liang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217062 · Cited by 15
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
Berry, D., Moldoveanu, D., Rajkumar, S., Lajoie, M., Lin, T., Tchelougou, D., Sakthivel, S., Sharon, I., Bernard, A., Pelletier, S., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115365 · Cited by 15
Zhang, Z., Zhai, M., Bao, S., Sun, X., Chen, R., Wang, B., Yang, F., Yang, L., & Zhou, M. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.017 · Cited by 17
STUB1 is an intracellular checkpoint for interferon gamma sensing
Ng, S., Lim, S., Sim, A. C. N., Mangadu, R., Lau, A., Zhang, C., Martinez, S. B., Chandramohan, A., Lim, U.-M., Ho, S. S. W., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18404-4 · Cited by 15
Gong, Z., Jia, Q., Guo, J., Li, C., Xu, S., Jin, Z., Chu, H., Wan, Y. Y., Zhu, B., & Zhou, Y. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00371-1 · Cited by 15
Tumor Microenvironment Modulates Immunological Outcomes of Myeloid Cells with mTORC1 Disruption
Ding, C., Sun, X., Wu, C., Hu, X., Zhang, H., & Yan, J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801112 · Cited by 15
Snowbarger, J. M., Koganti, P., & Spruck, C. (2024) · Biomolecules · doi:10.3390/biom14101250 · Cited by 14
High-throughput screening for optimizing adoptive T cell therapies
Zhang, Y., Xu, Q., Gao, Z., Zhang, H., Xie, X., & Li, M. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00580-w · Cited by 14
Chen, D., Liu, P., Lin, J., Zang, L., Liu, Y., Zhai, S., Lu, X., Weng, Y., & Li, H. (2024) · Advanced Science · doi:10.1002/advs.202406624 · Cited by 14
Coleborn, E., Ghebosu, R. E., Wolfram, J., & Souza-Fonseca-Guimarães, F. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.05.038 · Cited by 14
Komatsu, S.-I., Kayukawa, Y., Miyazaki, Y., Kaneko, A., Ikegami, H., Ishiguro, T., Nakamura, M., Frings, W., Ono, N., Sakata, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16564-x · Cited by 14
McLean, B. J., Istadi, A., Clack, T., Vankan, M., Schramek, D., Neely, G. G., & Pajic, M. (2022) · Advanced Genetics · doi:10.1002/ggn2.202200014 · Cited by 14
Burdett, N., Hsu, K., Xiong, L., Rico, G. T., Beckmann, K., Karapetis, C. S., & Brown, M. P. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13177 · Cited by 14
Psoriasis and cancer: the role of inflammation, immunosuppression, and cancer treatment
Bruni, M., Lobefaro, F., Pellegrini, C., Mastrangelo, M., Gualdi, G., Esposito, M., Antonetti, P., Sanctis, P. D., Amerio, P., & Fargnoli, M. C. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2471093 · Cited by 13
Identification of Antigenic Targets
Gerber, H., Sibener, L. V., Lee, L. J., & Gee, M. H. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.002 · Cited by 13
Tan, X., Yi, C., Zhang, Y., Tang, N., Xu, Y., & Liu, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.768222 · Cited by 13
Wang, S., Li, W., Li, J., Guo, Z., Chen, J., & Hu, Z. (2025) · International Journal of Cancer · doi:10.1002/ijc.70117 · Cited by 12
Leveraging T cells for cancer immunotherapy
Bates, A., Fletcher, N. E., Gao, F., Pinho, M. P., & Dong, T. (2025) · Immunity & Inflammation · doi:10.1007/s44466-025-00007-z · Cited by 13
Lu, M., Yeh, M., Huang, C., Wang, S., Tsai, Y., Tsai, P., Ko, Y., Lin, C., Chen, K., Wei, Y., et al. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i1.140 · Cited by 12
Local delivery of superagonist gene based on polymer nanoparticles for cancer immunotherapy
Hong, Z., Zan, X., Yu, T., Hu, Y., Gou, H., Zheng, S., Gao, X., & Zhou, P. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.06.026 · Cited by 12
Zheng, Z., Lu, S., Wu, Y., Kayitmazer, A. B., Ahmad, A., Ramzan, N., Rafique, M. S., Yang, J., Zhou, X., Xu, Y., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.155024 · Cited by 12
Che, Y., Yang, Y., Suo, J., Chen, C., & Wang, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s329471 · Cited by 11
Lau, V. W. C., Mead, G. J., Varyova, Z., Mazet, J. M., Krishnan, A. Y., Roberts, E. W., Prota, G., Gileadi, U., Midwood, K. S., Cerundolo, V., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54791-0 · Cited by 11
Jiang, M., Qin, B., Li, X., Liu, Y., Guan, G., & You, J. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1837 · Cited by 11
Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer
Wu, N., Liu, F., Huang, Y., Su, X., Zhang, Y., Yu, L., & Liu, B. (2023) · Biomolecules · doi:10.3390/biom13010101 · Cited by 11
Mattes, A.-K., Gámez, M. P., Martin, E., Boryń, Ł. M., Baskaran, P., Huber, H. J., Schuler, M. J., Park, J. E., & Swee, L. K. (2023) · eLife · doi:10.7554/elife.84314 · Cited by 11
Wang, X., Chan, S., Chen, J., Xu, Y., Dai, L., Han, Q., Wang, Z., Zuo, X., Yang, Y., Zhao, H., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03239-y · Cited by 11
Hogg, S. J., Motorna, O., Kearney, C. J., Derrick, E. B., House, I. G., Todorovski, I., Kelly, M. J., Zethoven, M., Bromberg, K. D., Lai, A., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01316-5 · Cited by 10
Self-citationTumor hypoxia shapes natural killer cell anticancer activities
Retamal, M. A., Salazar‐Onfray, F., González, F. E., & Tittarelli, A. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02557-6 · Cited by 10
Girotti, A. W., Bazak, J., & Korytowski, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411559 · Cited by 10
Zhang, P., Ying, P.-T., Li, H., Zhao, N., Liu, R., Li, S., Xu, W., Tang, Y., & Tang, Y. (2023) · APOPTOSIS · doi:10.1007/s10495-023-01925-2 · Cited by 10
Bhutani, B., Sharma, V., Ganguly, N. K., & Rana, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117987 · Cited by 10
Driscoll, C., Rich, J. M., Yang, C. C., Nicolas, J. D., Isaacson, D. S., Silberman, P., Mi, X., Kumar, S. K. S. R., Zhang, H., Belknap, S. M., et al. (2025) · Journal of Inflammation · doi:10.1186/s12950-025-00445-x · Cited by 9
CRISPR screens define unified hallmarks of cancer cell-autonomous immune evasion
Huber, A., Djajawi, T. M., Rivera, S., Vervoort, S. J., & Kearney, C. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116738 · Cited by 9
Self-citationHarnessing Synthetic Lethal Interactions for Personalized Medicine
Shieh, G. S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010098 · Cited by 9
Shi, Z., Shen, Y., Liu, X., & Zhang, S. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70024 · Cited by 9
PRKCSH contributes to TNFSF resistance by extending IGF1R half-life and activation in lung cancer
Shin, G., Lee, H. M., Kim, N., Seo, S., Kim, K. P., & Kim, K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01147-1 · Cited by 9
Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID
Gee, S., Nelson, N., Bornot, A., Carter, N., Cuomo, M. E., Dovedi, S. J., Smith, P. D., Gianni, D., & Baker, D. J. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220916457 · Cited by 9
How CRISPR/Cas9 Gene Editing Is Revolutionizing T Cell Research
Johansen, K. H. (2021) · DNA and Cell Biology · doi:10.1089/dna.2021.0579 · Cited by 9
Lu, S., Zhang, C., Wu, H., Wang, J., Wang, J., Zhao, L., Ren, T., & Li, G. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101801 · Cited by 8
Batara, D. C., Kim, H., Phan, L. T., Kim, M., Son, Y., Lee, S., Park, S., Choi, Y. S., Beck, S., & Kim, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-72901-2 · Cited by 8
MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors
Li, X., Han, Y., Jin, Z., Jiang, K., Xue, K., Wang, J., Qian, Y., Xiang, Q., Zhu, S., Yan, R., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240959 · Cited by 8
CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion
Yuan, H., Zhu, L., Yang, L., Yi, Y., & Lv, T. (2025) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2025071 · Cited by 8
Vredevoogd, D. W., Apriamashvili, G., & Peeper, D. S. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100043 · Cited by 8
Tumor immune evasion: insights from CRISPR screens and future directions
Djajawi, T. M., Wichmann, J., Vervoort, S. J., & Kearney, C. J. (2023) · FEBS Journal · doi:10.1111/febs.17003 · Cited by 8
Self-citationGRB7 Plays a Vital Role in Promoting the Progression and Mediating Immune Evasion of Ovarian Cancer
Wen, L., Hu, W., Hou, S., Luo, C., Jin, Y., Zeng, Z., Zhang, Z., & Meng, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17081043 · Cited by 8
Uncovering key targets of success for immunotherapy in pancreatic cancer
Pretta, A., Lai, E., Persano, M., Donisi, C., Pinna, G., Cimbro, E., Parrino, A., Spanu, D., Mariani, S., Liscia, N., et al. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2010044 · Cited by 8
Epithelial cell competition is promoted by signaling from immune cells
Zhu, Y., Wunderlich, Z., & Lander, A. D. (2025) · Nature Communications · doi:10.1038/s41467-025-59130-5 · Cited by 7
Liu, S., Yuan, Y., He, J., Zhou, Y., Wang, Y., Ye, X., Wang, J., & Zhang, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1666121 · Cited by 7
Wu, M., Yang, S., Yang, Z., Fan, J., Lomeli, S. H., Dharanipragada, P., Moriceau, G., Damoiseaux, R. D., Kelley, M. C., Granada, C. N. P., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.001 · Cited by 7
Phosphoprotein dynamics of interacting T cells and tumor cells by HySic
Ibáñez‐Molero, S., Pruijs, J. T. M., Atmopawiro, A., Wang, F., Terry, A. M., Altelaar, M. A. F., Peeper, D. S., & Stecker, K. E. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113598 · Cited by 7
Identification of DDX60 as a Regulator of MHC-I Class Molecules in Colorectal Cancer
Geng, N., Hu, T., & He, C. (2022) · Biomedicines · doi:10.3390/biomedicines10123092 · Cited by 7
Chen, Q., Gao, F., Wu, J., Zhang, K.-M., Du, T., Chen, Y., Cai, R., Zhao, D., Deng, R., & Tang, J. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1735 · Cited by 7
TBK1 inhibition unleashes RIPK1, resensitizing tumors to immunotherapy
Kelliher, M. A., & Fitzgerald, K. A. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.009 · Cited by 7
Harnessing Immunogenic Cell Death to Boost the Impact of Radiation Therapy
Mannion, J., & Meier, P. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000780 · Cited by 6
RNF31 promotes tumorigenesis via inhibiting RIPK1 kinase-dependent apoptosis
Zhang, J., Tu, H., Zheng, Z., Zhao, X., & Lin, X. (2023) · Oncogene · doi:10.1038/s41388-023-02669-8 · Cited by 6
Zhang, X.-X., Yu, X., Zhu, L., & Luo, J.-H. (2023) · Medicine · doi:10.1097/md.0000000000035923 · Cited by 6
Xu, Y., Xu, T., Huang, C., Amakye, W. K., Liu, L., Fan, J., Zhu, Y., Yao, M., & Ren, J. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134941 · Cited by 6
Listening in on Multicellular Communication in Human Tissue Immunology
Albers, J. J., & Pelka, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884185 · Cited by 6
Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses
Goldufsky, J. W., Daniels, P., Williams, M. D., Gupta, K. H., Lyday, B., Chen, T., Singh, G., Kaufman, H. L., Zloza, A., & Marzo, A. L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04344-8 · Cited by 6
Wang, Y., Khalil, A., Kamar, A., Du, M., Dinh, T., McFarland, C. D., & Wang, Z. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1304425 · Cited by 6
Improving Cancer Immunotherapy with CRISPR‐Based Technology
Li, Z., & Teng, F. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900253 · Cited by 6
Genetic Screening for Novel Regulators of Immune Checkpoint Molecules
Arens, R., & Scheeren, F. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.005 · Cited by 6
Liao, C., Engelberts, P. J., van Dijk, M., Timmermans, A. M., Martens, J. W. M., Neubert, E., & Danen, E. H. J. (2025) · European Journal of Immunology · doi:10.1002/eji.202451589 · Cited by 5
Ye, C., Chen, X., Chen, Z., Liu, S., Kong, R., Lin, W., Zhu, M., Sun, X., & Xu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604394 · Cited by 5
Sinha, S., Panda, A. K., das Neves, R. X., Nwosu, Z. C., Xu, K., van Beek, E., Desai, P. P., Sindiri, S., Chempati, S., Remmert, K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1055 · Cited by 5
Slavic-Obradovic, K., Ebner, F., Artemov, A. V., Miotto, M., Traexler, P.-E., Jacob, R., Thanh, H. P. T., Ruzicka, R., Wernitznig, A., Baumann, I., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102313 · Cited by 5
Guo, Z., Li, X., Huang, L., Yan, Y., Gao, M., & Huang, J. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01706-x · Cited by 5
A TAK1 cytokine toxicity checkpoint controls anti-cancer immunity
Djajawi, T. M., Huber, A., Rivera, S., Srivaths, A., Salehi, M., Gunay, G., Gerak, C., Neil, L., Ozaydin, O., Voulgaris, O., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116665 · Cited by 5
Self-citationFernando, W., Clucas, J., Rizzo, A., Singer, R., Goode, E., Tiu, C., Layzell, S., Konecnik, J., Wilson, R., John, S. W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70133-8 · Cited by 5
Zhang, H., Hong, Z., Li, P., Jiang, H., Wu, P., & Chen, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.811660 · Cited by 5
Cho, J.-W., Cao, J., & Hemberg, M. (2024) · Genome biology · doi:10.1186/s13059-024-03201-1 · Cited by 5
Li, C., Huang, Y., Yi, X., Tang, Y., Okita, R., & He, J. (2024) · Translational Cancer Research · doi:10.21037/tcr-24-434 · Cited by 5
Martinez, R., Finocchiaro, C., Delhaye, L., Gysens, F., Anckaert, J., Trypsteen, W., Versteven, M., Lion, E., Lint, S. V., Vermaelen, K., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444886 · Cited by 5
Hypothesis: Mutations and Immunosurveillance in Obesity-Associated Colorectal Cancer
Lazarova, D. L., & Bordonaro, M. (2022) · Journal of Cancer · doi:10.7150/jca.76052 · Cited by 5
Modulation of signaling cross-talk between pJNK and pAKT generates optimal apoptotic response
Biswas, S., Tikader, B., Kar, S., & Viswanathan, G. A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010626 · Cited by 5
Heterogeneous characteristics of γδ T cells in peripheral blood of diffuse large B-cell lymphoma
Wang, P., Lai, W., Zheng, J., Wu, X., Zhan, J., Yi, T., Jin, Z., & Wu, X. (2025) · Biomarker Research · doi:10.1186/s40364-025-00795-x · Cited by 4
Bioorthogonal optimized virus immuno-nanomedicine (BOVIN)
Peng, W., Du, Y., Cui, L., Xiao, Y., Li, L., Yan, L., Gu, Y., Zhang, L., Li, B., Wang, Z., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66089-w · Cited by 4
Korbelik, M., Girotti, A. W., & Kessel, D. H. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02651-3 · Cited by 4
Park, J. H., Lee, D. U., Jeong, J., Jung, K. H., & Hong, S. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.017 · Cited by 4
Sun, N. D., Carr, A. R., Krogman, E. N., Chawla, Y. K., Zhong, J., Guttormson, M. C., Chan, M., Hsu, M. A., Dong, H., Bogunovic, D., et al. (2026) · Science Signaling · doi:10.1126/scisignal.adz7366 · Cited by 4
Jiang, X., Asad, M., Li, L., Sun, Z., Milanese, J., Liao, B., & Wang, E. (2020) · Quantitative Biology · doi:10.1007/s40484-020-0212-7 · Cited by 4
The future of immune checkpoint combinations with tumor-targeted small molecule drugs
Sceneay, J., & Sinclair, C. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20210064 · Cited by 4
Rao, D., Lacroix, R., Rooker, A., Gomes, T., Stunnenberg, J. A., Valenti, M., Dimitriadis, P., Lin, C., de Bruijn, B., Krijgsman, O., et al. (2022) · Melanoma Research · doi:10.1097/cmr.0000000000000863 · Cited by 4
Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens
Yim, S., Hwang, W., Han, N., & Lee, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.884561 · Cited by 4
The CRISPR System and Cancer Immunotherapy Biomarkers
Balan, V., & Wang, J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_14 · Cited by 4
Loss of Ubiquitin Ligase STUB1 Amplifies IFNγ-R1/JAK1 Signaling and Sensitizes Tumors to IFNγPreprint
Apriamashvili, G., Vredevoogd, D. W., Krijgsman, O., Bleijerveld, O. B., Ligtenberg, M. A., de Bruijn, B., Boshuizen, J., Altimari, D. M. D., Visser, N. L., Londino, J. D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.07.191650 · Cited by 4
Vanni, A., Matani, F., Bonaudo, C., Mazzoni, A., Capone, M., Lamacchia, G., Salvati, L., Bartoli, L., Francalanci, S., Petti, M., et al. (2025) · European Journal of Immunology · doi:10.1002/eji.202451681 · Cited by 3
Huska, J. D., Doyle, K. J., Purkal, J. J., Hrusch, C. L., Duggan, R., Boghaert, E. R., Souers, A. J., Phillips, D. C., & Tahir, S. K. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08013-0 · Cited by 3
Zefferino, R., & Conese, M. (2023) · Vaccines · doi:10.3390/vaccines11111701 · Cited by 3
Sosnowska, D., Cheung, T. S., Sarkar, J., Opzoomer, J. W., Feehan, K. T., Anstee, J. E., Woodman, C. A., Keddar, M. R., Clayton, K., Ali, S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.191017 · Cited by 3
Huo, J., Qi, J., & Ren, Q. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251375464 · Cited by 3
Heterogeneity in functional genetic screens: friend or foe?
Vredevoogd, D. W., & Peeper, D. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1162706 · Cited by 3
CRISPR technology for immuno-oncology applications
Wang, J., Balan, V., & Marincola, F. M. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.018 · Cited by 3
Metadata
- Authors
- Kearney, C. J., Vervoort, S. J., Hogg, S. J., Ramsbottom, K. M., Freeman, A. J., Lalaoui, N., Pijpers, L., Michie, J., Brown, K. K., Knight, D. A., Sutton, V., Beavis, P. A., Voskoboinik, I., Darcy, P. K., Silke, J., Trapani, J. A., Johnstone, R. W., & Oliaro, J.
- Affiliations
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3052, Australia.
- Corresponding author
- Kearney, Conor J.
- Vervoort, Stephin J.
- Johnstone, Ricky W.
- Oliaro, Jane
- ORCID
- Venue
- Science Immunology
- Published
- 2018-05-04
- Volume
- 3
- Issue
- 23
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2804568941
- Cited by
- 381
- References
- 46
- Citations by year
- 2026: 20 · 2025: 59 · 2024: 61 · 2023: 59 · 2022: 55 · 2021: 54 · 2020: 38 · 2019: 26 · 2018: 7
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Victorian Cancer Agency
- National Health and Medical Research Council
- Cancer Council Victoria
- National Breast Cancer Foundation (ECF-17-005)
- Netherlands Organization for Scientific Research
- Peter MacCallum Cancer Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- tumor immune evasion, TNF signaling, T cell-mediated killing, NK cell-mediated killing, interferon signaling, antigen presentation, immune surveillance, tumor immunology
- MeSH terms
- Animals, Interferon-gamma, Killer Cells, Natural, Tumor Necrosis Factor-alpha, Antigen Presentation, CD8-Positive T-Lymphocytes, Tumor Escape, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.